Our Solutions for Transformative Patient Outcomes

Brain Mapping

Our proprietary AI-driven system, is being developed to leverage multiple brain imaging models and sophisticated machine learning algorithms to uncover the hidden connections within the human brain.

Traditionally, understanding the brain has been limited by the difficulty of distinguishing between cause and effect. Which brain regions are driving behaviors, and which are simply responding to them?

Despite the challenge of individual brain differences, we aim to customize brain mapping for each patient, tailoring treatments based on their specific symptoms and medical history.

This platform is designed to enable us to:

  • Transform complex brain images into functional models
  • Identify cross-patient neural similarities and differences
  • Uncover novel, widely applicable treatment approaches
  • Analyze intricate brain activation patterns and neural connections

We are focused on exploring several areas using MyndTec AI, including:

  • Mapping neural pathways and identifying alternative routes
  • Characterizing brain patterns associated with various conditions
  • Developing targeted treatments for affected brain regions

The Benefits

  • Personalized Treatment Plans: Our approach enables highly tailored therapies based on each individual’s unique brain patterns.
  • Enhanced Understanding: By revealing the underlying causes of brain disorders, we’re advancing our knowledge of the human mind.
  • Promising Future: Our technology has the potential to revolutionize the treatment of various neurological and psychiatric conditions.

Through our initial work on MyndTec AI Mobility, we would look to enhance the foundational MyndTec AI platform for its broader use, including:

  • Identify additional brain tracts for new treatments and therapies, such as personalized pain management
  • Explore new neural pathways and brain regions
  • Broaden the spectrum of interpretable brain signals

Neuromodulation

Neuromodulation is a rapidly advancing medical field focused on adjusting nervous system activity within the central, peripheral, or autonomic systems. This discipline leverages targeted interventions to manage chronic neurological and psychiatric disorders by modifying abnormal neural activity. Techniques like spinal cord stimulation, deep brain stimulation (DBS), vagus nerve stimulation (VNS), and transcranial magnetic or electrical stimulation are used to address specific neural circuits associated with symptoms. These interventions aim to restore function and improve quality of life by optimizing neural pathways.

Devices in neuromodulation span a spectrum of invasiveness, from non-invasive technologies, such as FES systems, to implantable devices like spinal cord stimulators. These tools enable clinicians to tailor treatments, addressing conditions ranging from chronic pain to motor impairments. Advances in artificial intelligence (AI) are further enhancing neuromodulation by improving patient selection, therapy optimization, and real-time decision-making. AI algorithms analyze large, multi-dimensional datasets to identify the best candidates for treatment, predict therapy outcomes, and fine-tune device parameters. This reduces trial-and-error approaches, shortens treatment cycles, and personalizes care, offering better outcomes for patients while optimizing clinical workflows.

MyndTec’s latest innovation to improve outcomes for spinal cord stimulation (SCS) patients focuses on enhancing patient selection through the integration of advanced machine learning within a decision support system (ML-DSS). By analyzing comprehensive patient datasets—including demographics, pain characteristics, treatment history, and therapeutic responses—the ML-DSS identifies individuals most likely to benefit from SCS therapy. This innovation reduces the trial-and-error process in patient selection, ensuring a higher success rate and more efficient use of resources. With its data-driven approach, MyndTec’s ML-DSS empowers healthcare providers to deliver precision care, improving outcomes and transforming the management of chronic pain. Learn more about this personalized AI-driven solution.

MyndMove™ is an advanced non-invasive neuromodulation therapy designed to restore voluntary motor function in individuals with upper-limb paralysis caused by stroke or quadriplegia. Using functional electrical stimulation (FES), MyndMove™ delivers targeted electrical impulses to stimulate neural pathways associated with movement while patients actively engage in attempting the desired actions. This process leverages neuroplasticity, enabling the brain to reorganize and establish new neural connections for sustained functional recovery. Clinical studies highlight significant improvements in voluntary movement, muscle strength, and quality of life for both acute and chronic paralysis patients. As a non-invasive and effective therapy, MyndMove™ exemplifies the transformative potential of neuromodulation in restoring independence and improving outcomes for individuals with severe motor impairments. Learn more about MyndMove

Regeneration

This technology has the potential to revolutionize brain regeneration it uses patented technology to stimulate growth of patients’ own stem cells, then migrates them to the site of brain injury. These cells mature into new functional neurons, repair the injury, and restore function

Technology Overview

The technology leverages the use of bi-phasic electrical stimulation to target areas of the brain for the migration of endogenous neural progenitor cells (NPC) to the site of damaged or diseased cells for the restoration of neural connections as a treatment for neurological disorders and injuries, such as Parkinson’s disease, Alzheimer’s disease and stroke. This form of neurostimulation, like deep brain stimulation, generally involves implanting two electrodes in the brain. One electrode is implanted near the subventricular zone (SVZ) of the lateral ventricle (LV) where NPCs reside and the other electrode at the site of the damaged tissue and connected to a neurostimulator. Once activated, electrical currents flow between the electrodes into the surrounding tissue, creating an electric field.

Pre-clinical testing of the technology in stroke models has shown that murine NPC survival, migration and differentiation can be modified by an electric field. Biphasic stimulation, which works by alternating the direction of the electrical charge between positive and negative resulting in zero net charge in the tissue, has the potential to allow for greater flexibility in adjusting stimulation parameters and in optimizing therapeutic outcomes while reducing the risk of unintended tissue damage or electrode corrosion generally associated with prolonged unidirectional stimulation.

Our Neural Regeneration Technology defeats multiple stem cell therapy roadblocks and is widely applicable Consistent and Reliable Stimulates growth of patient’s own stem cells — no manufacture or injection of stem cells, or manufacture of large number of stem cells is needed. This removes significant ethical and technical hurdles that have plagued stem cell therapies. No Safety or ethical concerns Patient is stimulated to produce their own stem cells in the brain as an outcome of therapy. Externally sourced stem cells, and the safety and ethical roadblocks that go with them are not needed. It is a platform technology to treat multiple indications.